CytomX Therapeutics Inc(NASDAQ:CTMX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $3.09M. Analysts estimated a revenue of $2.57M. Earnings per share were $-0.39. Analysts had estimated an EPS of $-0.41.
Several Insider Transactions has been reported to the SEC. On Jun 10, 2016, Timothy M Shannon (director) sold 48,427 shares at $10.05 per share price.Also, On Oct 16, 2015, William Michael Kavanaugh (CSO, Head Res.&Non-Clin. Dev.) purchased 5,000 shares at $12.00 per share price.On Oct 16, 2015, Frederick W Gluck (director) purchased 15,000 shares at $12.00 per share price, according to the Form-4 filing with the securities and exchange commission.
CytomX Therapeutics Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company’s pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company’s additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.